ICARE-LCS QUERI Partnered Evaluation Initiative: Integrating Comprehensive Tobacco Treatment to Enhance Lung Cancer Screening

NCT06745258 | Not Yet Recruiting

• 1 other identifier: PEX 24-002
• Study Type: observational
• Target: 7
• Locations: 1 country
• Sites: 1

Brief Summary

Lung cancer is the leading cause of cancer-related death among Veterans with 90% of cases attributable to smoking. Lung cancer screening (LCS) combined with smoking cessation saves the most lives. ICARE-LCS seeks to decrease health inequality and improve Veteran health by reducing smoking rates among Veterans receiving LCS. ICARE-LCS will use implementation methods to inform national cancer prevention efforts and build infrastructure necessary to support broad implementation of high-impact tobacco dependence treatment (TDT) processes in LCS programs.

Conditions

Lung Cancer Screening; Tobacco Dependence Treatment

Keywords

Lung Cancer; Lung Nodule; Tobacco; Lung Cancer Screening

Outcome Measures

Primary Outcomes (1)

• Receipt of Combined Tobacco Dependence Treatment

  Participation in counseling and pharmacotherapy within 90 days of lung cancer screening referral

  Approximately 3 years

Secondary Outcomes (5)

• Number of Veterans Receiving ANY Tobacco Dependence Treatment Therapy

  Approximately 3 years

• Number of Veterans Receiving of Pharmacotherapy or Counseling Alone

  Approximately 3 years

• Cost Associated with Tobacco Dependence Treatment Among Lung Cancer Screening Participants who Smoke

  Approximately 3 years

• Rate of Short-term Cessation Among Veterans In Lung Cancer Screening who Smoke

  Approximately 3 years

• Implementation Outcomes Assessed at Participating Sites

  Approximately 3 years

Study Arms (2)

Veterans Participating in Lung Cancer Screening who Smoke

Veterans participating in lung cancer screening who smoke and are receiving care at participating VA medical centers

Participating VA Medical Centers

Seven sites that have agreed to participate in implementation intervention

Other: External Facilitation

Interventions

External Facilitation OTHER

Multi-component facilitation strategy to address identified implementation needs

Participating VA Medical Centers

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Participating VA Medical Centers

You may qualify if:

• This is a VAMC based Quality Improvement Partnered Evaluation Initiative. VA sites from around the country that agreed to participate are included.

You may not qualify if:

• N/A

Sponsors & Collaborators

• VA Office of Research and Development: lead
• VA Oncology and Precision Medicine: collaborator
• VA Tobacco Use Treatment National Program Office: collaborator
• VA National Center for Lung Cancer Screening: collaborator

Study Sites (1)

Minneapolis VA Health Care System, Minneapolis, MN

Minneapolis, Minnesota, 55417-2309, United States

Location

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Anne C. Melzer, MD MS

  Minneapolis VA Health Care System, Minneapolis, MN

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Anne C Melzer, MD MS

CONTACT

(612) 725-2000; Anne.Melzer2@va.gov

Megan E Campbell

CONTACT

(612) 725-2000; megan.campbell@va.gov

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: OTHER
• Sponsor Type: FED
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 16, 2024
• First Posted: December 20, 2024
• Study Start: October 1, 2026
• Primary Completion (Estimated): June 30, 2027
• Study Completion (Estimated): June 30, 2027
• Last Updated: May 26, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)